GlassScriptPhysician profile
Amelia Hill
NPI 1205316858
$3,363.27
in general payments reported to CMS, 2019-2025
34 companies · $43.09 in 2025
The $43.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $362 · 2023: $1,314 · 2024: $744 · 2025: $43.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.56 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $450.76 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $228.08 | 2021-2024 | |
| Insulet Corporation | $224.39 | 2021-2025 | Omnipod |
| Abbott Laboratories | $208.94 | 2021-2024 | Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $200.87 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $152.53 | 2021-2023 | Korlym |
| Cequr Corporation | $124.05 | 2022-2024 | Cequr Simplicity |
| Mannkind Corporation | $115.60 | 2021 | |
| Sanofi-Aventis U.S. LLC | $112.61 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.98 | 2021-2023 | |
| Ascensia Diabetes Care US INC. | $102.96 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $101.75 | 2021 | |
| Amgen INC. | $93.96 | 2021-2024 | Repatha, Tepezza |
| Boston Scientific Corporation | $84.16 | 2022-2023 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $76.07 | 2021-2024 | Minimed 780g |
| Antares Pharma, INC. | $56.49 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $54.35 | 2021-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $48.76 | 2023 | |
| Nestle Healthcare Nutrition INC. | $44.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.93 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.09 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Tandem Diabetes Care, INC. | $29.85 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar, INC. | $28.07 | 2023-2024 | |
| Intuity Medical INC | $26.04 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Alexion Pharmaceuticals, INC. | $24.08 | 2023 | Strensiq |
| Dexcom, INC. | $24.00 | 2022 | |
| Horizon Therapeutics Plc | $18.57 | 2022 | |
| Radius Health, INC. | $18.32 | 2021 | |
| Shield Therapeutics INC | $17.42 | 2023 | Accrufer |
| Recordati_rare_diseases_inc. | $16.02 | 2021 | |
| Esperion Therapeutics, INC. | $14.38 | 2021 | |
| Ibsa Pharma INC. | $13.31 | 2021 | |
| Currax Pharmaceuticals LLC | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.